Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Opdivo Tops Japan Drug Ranking for 14 Months Running: Encise
March 8, 2023
- Japan Ethical Drug Sales Grow 3.5% in January: Crecon
March 8, 2023
- Teva Takeda Prepping for Listing of Allermist AG in June
March 8, 2023
- Kyorin Out-Licenses Vibegron to Sumitomo in 5 Asian Markets
March 7, 2023
- Azilva, Abraxane, and More Major Meds Get Add-On PMPs under Ad-Hoc Rule in FY2023: Poll
March 7, 2023
- Drug Makers Wary of Rush Demand Tied to Unprofitability Re-Pricing, Some Curb Orders
March 7, 2023
- Teijin Grants Global Rights for Kidney Disease Med to Novartis
March 7, 2023
- FDA Accepts Eisai’s Lecanemab Application for Early July Target
March 6, 2023
- Generic Makers See Milder Cuts in FY2023 Revision, Nipro to Get 1%-Plus Net Hike: Jiho Poll
March 6, 2023
- 2023 Price Cut for Top-Tier, 2nd-Tier Firms at 1-4%, Tsumura Only Original Drug Maker to See Net Rise: Jiho Poll
March 6, 2023
- Sumitomo Pharma Drops Cancer Drug Candidate Dubermatinib
March 6, 2023
- Alfresa Pharma Gets Japan Rights to Keio Biotech’s ALS Drug
March 3, 2023
- Biogen Japan, Eisai to End MS Copromotion Pact in Japan
March 3, 2023
- Neil MacGregor Takes Over as President of Amgen Japan
March 2, 2023
- Nichi-Iko to Discontinue 221 Additional Products, Generic Peers Looking into Impact
March 2, 2023
- Eylea 8 mg Filed in Japan to Extend Dosing Intervals: Bayer
March 2, 2023
- Nichi-Iko Exits North American Market, Biosimilar Biz with Sagent Sell-Off
March 1, 2023
- AstraZeneca Files Anti-RSV Antibody Nirsevimab in Japan
March 1, 2023
- Nippon Chemiphar Out-Licenses XOR Inhibitor to Chinese Pharma
March 1, 2023
- UCB Japan Files Rozanolixizumab for Generalized Myasthenia Gravis
March 1, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…